AgNORs Count Correlates Better than Grading with the Effect of Chemotherapy in Serous Ovarian Cancer

Polish Journal of Pathology

Volumn 54, Issue 4, 2003, Pages 239-242

  Gottwald, Leszek ^a,b   Danilewicz, Marian ^a   Suzin, Jacek ^a   Wójcik Krowiranda, Katarzyna ^a   Bieńkiewicz, Andrzej ^a  

^a University Medical School   (Poland)

^b University Medical School of Lodz   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CELL NUCLEUS; CHROMOSOME NOR; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTADENOCARCINOMA; DISSEMINATED CANCER; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; METASTASIS; MULTIMODALITY CANCER THERAPY; OVARY CANCER; OVARY TUMOR; PATHOLOGY; PROGNOSIS; QUANTITATIVE ANALYSIS; REOPERATION; SILVER STAINING; TREATMENT OUTCOME;

ADULT; AGED; CELL NUCLEUS; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NUCLEOLUS ORGANIZER REGION; OVARIAN NEOPLASMS; PROGNOSIS; SILVER STAINING; TREATMENT OUTCOME;

EID: 1242307952     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bieńkiewicz A, Gottwald L, Suzin J: Final staging of ovarian cancer classified during surgery as stage I (FIGO). Int J Gynecol Obstet 2000, Suppl, P3.16.15.
2. Chiusa L, Galliano D, Formiconi A, Di Primio O, Pich A: High and low risk prostate carcinoma determined by histologic grade and proliferative activity. Cancer 1997, 79(10), 1956-1963.
3. Clarc TG, Stewart ME, Altman DG, Gabra H, Smyth JF: A prognostic model of ovarian cancer. Br J Cancer 2001, 85(7), 944-952.
4. Costa Ad, de Araujo NS, Pinto Dd, de Araujo VC: PCNA/AgNOR and Ki-67/AgNOR double staining in oral squamous cell carcinoma. J Oral Pathol Med 1999, 28(10), 438-441.
5. Criscuolo M, Martinelli AM, Migaldi M, Zunarelli E, Bergamaschi M, Falchi AM, De Gaetani C: Prognostic significance of nucleolar organizer regions in ovarian epithelial tumors. Int J Gynecol Pathol 1993, 12(3), 259-263.
6. Crocker J, Boldy D, Egan M: How should we count AgNORs? Proposals for a standardized approach. J Pathol 1989, 158, 185-188.
7. Decker DG, Malkasian GD, Taylo WF: Prognostic importance of histologic grading in ovarian carcinoma. Natl Cancer Inst Monogr 1975, 42, 15-18.
8. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Malignant Neoplasms in Poland in 1999. M. Sklodowska-Curie Centre of Oncology. The National Register of Neoplasms. Warsaw 2002.
9. Ghazizadeh M, Sasaki Y, Araki T, Konishi H, Aihara K: Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses. Am J Clin Pathol 1997, 107(4), 451-458.
10. Howell WM, Black DA: Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: a 1-step method. Experimentia 1980, 36, 1014-1015.
11. Jeleń M, Blok K, Blok R, Leśkow E, Gruszczyń ska-Szkudlarek T: Regions of nuclear organisations (AgNORs) and Ki-67 antigen expression from the cervix and cervical canal smears with respect to changes in ASCUS and AGUS (atypical cells of unspecified importance) according to the Bethesda cytological system of classification. Ginekol Pol 2002, 77(12), 1192-1198.
12. Khattech A, Spatz A, Prade M, Duvillard P, Charpentier P, Bognel C, Michel G, Lhomme C: Nucleolar organizer regions in ovarian tumors: discrimination between carcinoma and borderline tumor. Int J Pathol 1992, 11(1), 11-14.
13. Kumar A, Kushwaha AK, Kumar M, Gupta S: Argyrophilic nucleolar organizer regions: their value and correlation with clinical prognostic factors in breast carcinoma. J Surg Oncol 1997, 65(3), 201-204.
14. Markowska J: Ovarian Cancer. Springer PWN, Warszawa 1997, 9-10.
15. Mauri FA, Scampini S, Aldovini D, Ferrero S, Barbareschi M, Dalla Palma P: AgNOR distribution in serous tumours of the ovary. Pathologica 1990, 82(1081), 487-492.
16. Miller B, Flax S, Dockter M, Photopulos G: Nucleolar organizer regions in adenocarcinoma of the uterine cervix. Cancer 1994, 74 74(12), 3142-3145.
17. Miller B, Morris M, Silva E: Nucleolar organizer regions: a potential prognostic factor in adenocarcinoma of the endometrium. Gynecol Oncol 1994, 54(2), 137-141.
18. Moss C, Kaye S: Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 2002, 38, 1701-1707.
19. Muso H: Long-term prognostic factors for chemotherapy of ovarian cancer. Osaka City Med J 1998, 44(2), 155-171.
20. Nakae S, Nakamura T, Ikegawa R, Yoshioka H, Shirono J, Tabuschi Y: Evaluation of argyrophilic nucleolar organizer region and proliferating cell nuclear antigen in colorectal cancer. J Surg Oncol 1998, 69(1), 28-35.
21. Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet J: Improvement in the staining and in the visualization of the argyrophilic proteins of the Nucleolar Organizer Regions at the optical level. Histochem J 1986, 18, 5-14.
22. Sirri V, Roussel P, Hernandez-Verdun D: The AgNOR proteins: qualitative and quantitative changes during the cell cycle. Micron 2000, 31(2), 121-126.
23. Sujathan K, Kannan S, Raveendran-Pillai K, Chandralekha B, Sreedevi-Amma N, Krishnan-Nair M: Significance of AgNOR count in differentiating malignant cells from reactive mesothelial cells in serous effusions. Acta Cytologica 1996, 40(4), 724-728.
24. Terlikowski S, Lenczewski A, Famulski W, Sulkowski S, Kulikowski M: Expression of nucleolar organizer regions (NORs) in ovarian epithelial tumors. Folia Histochem Cytobiol 2001, 39(2), 161-162.
25. Wierzchniewska A, Wa̧growska-Danilewicz M, Danilewicz M: Value of AgNOR counts and morphometric analysis of nuclear parameters in premalignant and malignant lesions of the uterine cervix. Pol J Pathol 1998, 49(4), 297-301.
26. Zergeroglu S, Aksakal O, Demirturk F, Gokmen O: Prognostic importance of the nucleolar organizer region score in ovarian epithelial tumors. Gynecol Obstet Invest 2001, 51(1), 60-63.